Late Stage Chronic Kidney Disease Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Late Stage Chronic Kidney Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028. Segment by Type Calcimimetics Vitamin D Sterols Potassium Binders Others Segment by Application Hospital Pharmacies Online Pharnacies Retail Pharmacies By Company AbbVie Amgen Ardelyx AstraZeneca Deltanoid Akebia Therapeutics Kyowa Hakko Kirin OPKO Health Vifor Pharma Sanofi Shield Therapeutics Shire Spectrum ZS Pharma By Region North America United States Canada Europe Germany France UK Italy Russia Nordic Countries Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA
1 Report Business Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Calcimimetics 1.2.3 Vitamin D Sterols 1.2.4 Potassium Binders 1.2.5 Others 1.3 Market by Application 1.3.1 Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Hospital Pharmacies 1.3.3 Online Pharnacies 1.3.4 Retail Pharmacies 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Late Stage Chronic Kidney Disease Drugs Market Perspective (2017-2028) 2.2 Late Stage Chronic Kidney Disease Drugs Growth Trends by Region 2.2.1 Late Stage Chronic Kidney Disease Drugs Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Late Stage Chronic Kidney Disease Drugs Historic Market Size by Region (2017-2022) 2.2.3 Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Region (2023-2028) 2.3 Late Stage Chronic Kidney Disease Drugs Market Dynamics 2.3.1 Late Stage Chronic Kidney Disease Drugs Industry Trends 2.3.2 Late Stage Chronic Kidney Disease Drugs Market Drivers 2.3.3 Late Stage Chronic Kidney Disease Drugs Market Challenges 2.3.4 Late Stage Chronic Kidney Disease Drugs Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Late Stage Chronic Kidney Disease Drugs Players by Revenue 3.1.1 Global Top Late Stage Chronic Kidney Disease Drugs Players by Revenue (2017-2022) 3.1.2 Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Players (2017-2022) 3.2 Global Late Stage Chronic Kidney Disease Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Late Stage Chronic Kidney Disease Drugs Revenue 3.4 Global Late Stage Chronic Kidney Disease Drugs Market Concentration Ratio 3.4.1 Global Late Stage Chronic Kidney Disease Drugs Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Late Stage Chronic Kidney Disease Drugs Revenue in 2021 3.5 Late Stage Chronic Kidney Disease Drugs Key Players Head office and Area Served 3.6 Key Players Late Stage Chronic Kidney Disease Drugs Product Solution and Service 3.7 Date of Enter into Late Stage Chronic Kidney Disease Drugs Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Late Stage Chronic Kidney Disease Drugs Breakdown Data by Type 4.1 Global Late Stage Chronic Kidney Disease Drugs Historic Market Size by Type (2017-2022) 4.2 Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Type (2023-2028) 5 Late Stage Chronic Kidney Disease Drugs Breakdown Data by Application 5.1 Global Late Stage Chronic Kidney Disease Drugs Historic Market Size by Application (2017-2022) 5.2 Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Late Stage Chronic Kidney Disease Drugs Market Size (2017-2028) 6.2 North America Late Stage Chronic Kidney Disease Drugs Market Size by Type 6.2.1 North America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2017-2022) 6.2.2 North America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2023-2028) 6.2.3 North America Late Stage Chronic Kidney Disease Drugs Market Share by Type (2017-2028) 6.3 North America Late Stage Chronic Kidney Disease Drugs Market Size by Application 6.3.1 North America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2017-2022) 6.3.2 North America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2023-2028) 6.3.3 North America Late Stage Chronic Kidney Disease Drugs Market Share by Application (2017-2028) 6.4 North America Late Stage Chronic Kidney Disease Drugs Market Size by Country 6.4.1 North America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2017-2022) 6.4.2 North America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2023-2028) 6.4.3 U.S. 6.4.4 Canada 7 Europe 7.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size (2017-2028) 7.2 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type 7.2.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2017-2022) 7.2.2 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2023-2028) 7.2.3 Europe Late Stage Chronic Kidney Disease Drugs Market Share by Type (2017-2028) 7.3 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application 7.3.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2017-2022) 7.3.2 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2023-2028) 7.3.3 Europe Late Stage Chronic Kidney Disease Drugs Market Share by Application (2017-2028) 7.4 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country 7.4.1 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2017-2022) 7.4.2 Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2023-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size (2017-2028) 8.2 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type 8.2.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type (2017-2022) 8.2.2 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type (2023-2028) 8.2.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Share by Type (2017-2028) 8.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application 8.3.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application (2017-2022) 8.3.2 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application (2023-2028) 8.3.3 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Share by Application (2017-2028) 8.4 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region 8.4.1 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region (2017-2022) 8.4.2 Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region (2023-2028) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Late Stage Chronic Kidney Disease Drugs Market Size (2017-2028) 9.2 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Type 9.2.1 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2017-2022) 9.2.2 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2023-2028) 9.2.3 Latin America Late Stage Chronic Kidney Disease Drugs Market Share by Type (2017-2028) 9.3 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Application 9.3.1 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2017-2022) 9.3.2 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2023-2028) 9.3.3 Latin America Late Stage Chronic Kidney Disease Drugs Market Share by Application (2017-2028) 9.4 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Country 9.4.1 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2017-2022) 9.4.2 Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2023-2028) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size (2017-2028) 10.2 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type 10.2.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type (2017-2022) 10.2.2 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type (2023-2028) 10.2.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Share by Type (2017-2028) 10.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application 10.3.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application (2017-2022) 10.3.2 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application (2023-2028) 10.3.3 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Share by Application (2017-2028) 10.4 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country 10.4.1 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country (2017-2022) 10.4.2 Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country (2023-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 AbbVie 11.1.1 AbbVie Company Details 11.1.2 AbbVie Business Overview 11.1.3 AbbVie Late Stage Chronic Kidney Disease Drugs Introduction 11.1.4 AbbVie Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.1.5 AbbVie Recent Developments 11.2 Amgen 11.2.1 Amgen Company Details 11.2.2 Amgen Business Overview 11.2.3 Amgen Late Stage Chronic Kidney Disease Drugs Introduction 11.2.4 Amgen Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.2.5 Amgen Recent Developments 11.3 Ardelyx 11.3.1 Ardelyx Company Details 11.3.2 Ardelyx Business Overview 11.3.3 Ardelyx Late Stage Chronic Kidney Disease Drugs Introduction 11.3.4 Ardelyx Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.3.5 Ardelyx Recent Developments 11.4 AstraZeneca 11.4.1 AstraZeneca Company Details 11.4.2 AstraZeneca Business Overview 11.4.3 AstraZeneca Late Stage Chronic Kidney Disease Drugs Introduction 11.4.4 AstraZeneca Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.4.5 AstraZeneca Recent Developments 11.5 Deltanoid 11.5.1 Deltanoid Company Details 11.5.2 Deltanoid Business Overview 11.5.3 Deltanoid Late Stage Chronic Kidney Disease Drugs Introduction 11.5.4 Deltanoid Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.5.5 Deltanoid Recent Developments 11.6 Akebia Therapeutics 11.6.1 Akebia Therapeutics Company Details 11.6.2 Akebia Therapeutics Business Overview 11.6.3 Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Introduction 11.6.4 Akebia Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.6.5 Akebia Therapeutics Recent Developments 11.7 Kyowa Hakko Kirin 11.7.1 Kyowa Hakko Kirin Company Details 11.7.2 Kyowa Hakko Kirin Business Overview 11.7.3 Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Introduction 11.7.4 Kyowa Hakko Kirin Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.7.5 Kyowa Hakko Kirin Recent Developments 11.8 OPKO Health 11.8.1 OPKO Health Company Details 11.8.2 OPKO Health Business Overview 11.8.3 OPKO Health Late Stage Chronic Kidney Disease Drugs Introduction 11.8.4 OPKO Health Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.8.5 OPKO Health Recent Developments 11.9 Vifor Pharma 11.9.1 Vifor Pharma Company Details 11.9.2 Vifor Pharma Business Overview 11.9.3 Vifor Pharma Late Stage Chronic Kidney Disease Drugs Introduction 11.9.4 Vifor Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.9.5 Vifor Pharma Recent Developments 11.10 Sanofi 11.10.1 Sanofi Company Details 11.10.2 Sanofi Business Overview 11.10.3 Sanofi Late Stage Chronic Kidney Disease Drugs Introduction 11.10.4 Sanofi Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.10.5 Sanofi Recent Developments 11.11 Shield Therapeutics 11.11.1 Shield Therapeutics Company Details 11.11.2 Shield Therapeutics Business Overview 11.11.3 Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Introduction 11.11.4 Shield Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.11.5 Shield Therapeutics Recent Developments 11.12 Shire 11.12.1 Shire Company Details 11.12.2 Shire Business Overview 11.12.3 Shire Late Stage Chronic Kidney Disease Drugs Introduction 11.12.4 Shire Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.12.5 Shire Recent Developments 11.13 Spectrum 11.13.1 Spectrum Company Details 11.13.2 Spectrum Business Overview 11.13.3 Spectrum Late Stage Chronic Kidney Disease Drugs Introduction 11.13.4 Spectrum Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.13.5 Spectrum Recent Developments 11.14 ZS Pharma 11.14.1 ZS Pharma Company Details 11.14.2 ZS Pharma Business Overview 11.14.3 ZS Pharma Late Stage Chronic Kidney Disease Drugs Introduction 11.14.4 ZS Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) 11.14.5 ZS Pharma Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Author Details 13.3 Disclaimer
List of Tables Table 1. Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028 Table 2. Key Players of Calcimimetics Table 3. Key Players of Vitamin D Sterols Table 4. Key Players of Potassium Binders Table 5. Key Players of Others Table 6. Global Late Stage Chronic Kidney Disease Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028 Table 7. Global Late Stage Chronic Kidney Disease Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 8. Global Late Stage Chronic Kidney Disease Drugs Market Size by Region (2017-2022) & (US$ Million) Table 9. Global Late Stage Chronic Kidney Disease Drugs Market Share by Region (2017-2022) Table 10. Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 11. Global Late Stage Chronic Kidney Disease Drugs Market Share by Region (2023-2028) Table 12. Late Stage Chronic Kidney Disease Drugs Market Trends Table 13. Late Stage Chronic Kidney Disease Drugs Market Drivers Table 14. Late Stage Chronic Kidney Disease Drugs Market Challenges Table 15. Late Stage Chronic Kidney Disease Drugs Market Restraints Table 16. Global Late Stage Chronic Kidney Disease Drugs Revenue by Players (2017-2022) & (US$ Million) Table 17. Global Late Stage Chronic Kidney Disease Drugs Revenue Share by Players (2017-2022) Table 18. Global Top Late Stage Chronic Kidney Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Late Stage Chronic Kidney Disease Drugs as of 2021) Table 19. Ranking of Global Top Late Stage Chronic Kidney Disease Drugs Companies by Revenue (US$ Million) in 2021 Table 20. Global 5 Largest Players Market Share by Late Stage Chronic Kidney Disease Drugs Revenue (CR5 and HHI) & (2017-2022) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Late Stage Chronic Kidney Disease Drugs Product Solution and Service Table 23. Date of Enter into Late Stage Chronic Kidney Disease Drugs Market Table 24. Mergers & Acquisitions, Expansion Plans Table 25. Global Late Stage Chronic Kidney Disease Drugs Market Size by Type (2017-2022) & (US$ Million) Table 26. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Type (2017-2022) Table 27. Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 28. Global Late Stage Chronic Kidney Disease Drugs Revenue Market Share by Type (2023-2028) Table 29. Global Late Stage Chronic Kidney Disease Drugs Market Size by Application (2017-2022) & (US$ Million) Table 30. Global Late Stage Chronic Kidney Disease Drugs Revenue Share by Application (2017-2022) Table 31. Global Late Stage Chronic Kidney Disease Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 32. Global Late Stage Chronic Kidney Disease Drugs Revenue Share by Application (2023-2028) Table 33. North America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2017-2022) & (US$ Million) Table 34. North America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2023-2028) & (US$ Million) Table 35. North America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2017-2022) & (US$ Million) Table 36. North America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2023-2028) & (US$ Million) Table 37. North America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2017-2022) & (US$ Million) Table 38. North America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2023-2028) & (US$ Million) Table 39. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2017-2022) & (US$ Million) Table 40. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Type (2023-2028) & (US$ Million) Table 41. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2017-2022) & (US$ Million) Table 42. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Application (2023-2028) & (US$ Million) Table 43. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2017-2022) & (US$ Million) Table 44. Europe Late Stage Chronic Kidney Disease Drugs Market Size by Country (2023-2028) & (US$ Million) Table 45. Asia Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type (2017-2022) & (US$ Million) Table 46. Asia Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Type (2023-2028) & (US$ Million) Table 47. Asia Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application (2017-2022) & (US$ Million) Table 48. Asia Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Application (2023-2028) & (US$ Million) Table 49. Asia Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region (2017-2022) & (US$ Million) Table 50. Asia Pacific Late Stage Chronic Kidney Disease Drugs Market Size by Region (2023-2028) & (US$ Million) Table 51. Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2017-2022) & (US$ Million) Table 52. Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Type (2023-2028) & (US$ Million) Table 53. Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2017-2022) & (US$ Million) Table 54. Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Application (2023-2028) & (US$ Million) Table 55. Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2017-2022) & (US$ Million) Table 56. Latin America Late Stage Chronic Kidney Disease Drugs Market Size by Country (2023-2028) & (US$ Million) Table 57. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type (2017-2022) & (US$ Million) Table 58. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Market Size by Type (2023-2028) & (US$ Million) Table 59. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application (2017-2022) & (US$ Million) Table 60. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Market Size by Application (2023-2028) & (US$ Million) Table 61. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country (2017-2022) & (US$ Million) Table 62. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Market Size by Country (2023-2028) & (US$ Million) Table 63. AbbVie Company Details Table 64. AbbVie Business Overview Table 65. AbbVie Late Stage Chronic Kidney Disease Drugs Product Table 66. AbbVie Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 67. AbbVie Recent Developments Table 68. Amgen Company Details Table 69. Amgen Business Overview Table 70. Amgen Late Stage Chronic Kidney Disease Drugs Product Table 71. Amgen Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 72. Amgen Recent Developments Table 73. Ardelyx Company Details Table 74. Ardelyx Business Overview Table 75. Ardelyx Late Stage Chronic Kidney Disease Drugs Product Table 76. Ardelyx Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 77. Ardelyx Recent Developments Table 78. AstraZeneca Company Details Table 79. AstraZeneca Business Overview Table 80. AstraZeneca Late Stage Chronic Kidney Disease Drugs Product Table 81. AstraZeneca Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 82. AstraZeneca Recent Developments Table 83. Deltanoid Company Details Table 84. Deltanoid Business Overview Table 85. Deltanoid Late Stage Chronic Kidney Disease Drugs Product Table 86. Deltanoid Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 87. Deltanoid Recent Developments Table 88. Akebia Therapeutics Company Details Table 89. Akebia Therapeutics Business Overview Table 90. Akebia Therapeutics Late Stage Chronic Kidney Disease Drugs Product Table 91. Akebia Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 92. Akebia Therapeutics Recent Developments Table 93. Kyowa Hakko Kirin Company Details Table 94. Kyowa Hakko Kirin Business Overview Table 95. Kyowa Hakko Kirin Late Stage Chronic Kidney Disease Drugs Product Table 96. Kyowa Hakko Kirin Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 97. Kyowa Hakko Kirin Recent Developments Table 98. OPKO Health Company Details Table 99. OPKO Health Business Overview Table 100. OPKO Health Late Stage Chronic Kidney Disease Drugs Product Table 101. OPKO Health Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 102. OPKO Health Recent Developments Table 103. Vifor Pharma Company Details Table 104. Vifor Pharma Business Overview Table 105. Vifor Pharma Late Stage Chronic Kidney Disease Drugs Product Table 106. Vifor Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 107. Vifor Pharma Recent Developments Table 108. Sanofi Company Details Table 109. Sanofi Business Overview Table 110. Sanofi Late Stage Chronic Kidney Disease Drugs Product Table 111. Sanofi Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 112. Sanofi Recent Developments Table 113. Shield Therapeutics Company Details Table 114. Shield Therapeutics Business Overview Table 115. Shield Therapeutics Late Stage Chronic Kidney Disease Drugs Product Table 116. Shield Therapeutics Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 117. Shield Therapeutics Recent Developments Table 118. Shire Company Details Table 119. Shire Business Overview Table 120. Shire Late Stage Chronic Kidney Disease Drugs Product Table 121. Shire Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 122. Shire Recent Developments Table 123. Spectrum Company Details Table 124. Spectrum Business Overview Table 125. Spectrum Late Stage Chronic Kidney Disease Drugs Product Table 126. Spectrum Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 127. Spectrum Recent Developments Table 128. ZS Pharma Company Details Table 129. ZS Pharma Business Overview Table 130. ZS Pharma Late Stage Chronic Kidney Disease Drugs Product Table 131. ZS Pharma Revenue in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) & (US$ Million) Table 132. ZS Pharma Recent Developments Table 133. Research Programs/Design for This Report Table 134. Key Data Information from Secondary Sources Table 135. Key Data Information from Primary Sources List of Figures Figure 1. Global Late Stage Chronic Kidney Disease Drugs Market Share by Type: 2021 VS 2028 Figure 2. Calcimimetics Features Figure 3. Vitamin D Sterols Features Figure 4. Potassium Binders Features Figure 5. Others Features Figure 6. Global Late Stage Chronic Kidney Disease Drugs Market Share by Application: 2021 VS 2028 Figure 7. Hospital Pharmacies Case Studies Figure 8. Online Pharnacies Case Studies Figure 9. Retail Pharmacies Case Studies Figure 10. Late Stage Chronic Kidney Disease Drugs Report Years Considered Figure 11. Global Late Stage Chronic Kidney Disease Drugs Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 12. Global Late Stage Chronic Kidney Disease Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 13. Global Late Stage Chronic Kidney Disease Drugs Market Share by Region: 2021 VS 2028 Figure 14. Global Late Stage Chronic Kidney Disease Drugs Market Share by Players in 2021 Figure 15. Global Top Late Stage Chronic Kidney Disease Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Late Stage Chronic Kidney Disease Drugs as of 2021) Figure 16. The Top 10 and 5 Players Market Share by Late Stage Chronic Kidney Disease Drugs Revenue in 2021 Figure 17. North America Late Stage Chronic Kidney Disease Drugs Market Size YoY (2017-2028) & (US$ Million) Figure 18. North America Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2017-2028) Figure 19. North America Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2017-2028) Figure 20. North America Late Stage Chronic Kidney Disease Drugs Market Size Share by Country (2017-2028) Figure 21. United States Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Canada Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Europe Late Stage Chronic Kidney Disease Drugs Market Size YoY (2017-2028) & (US$ Million) Figure 24. Europe Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2017-2028) Figure 25. Europe Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2017-2028) Figure 26. Europe Late Stage Chronic Kidney Disease Drugs Market Size Share by Country (2017-2028) Figure 27. Germany Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. France Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. U.K. Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Italy Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Russia Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Nordic Countries Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Asia-Pacific Late Stage Chronic Kidney Disease Drugs Market Size YoY (2017-2028) & (US$ Million) Figure 34. Asia Pacific Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2017-2028) Figure 35. Asia Pacific Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2017-2028) Figure 36. Asia Pacific Late Stage Chronic Kidney Disease Drugs Market Size Share by Region (2017-2028) Figure 37. China Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Japan Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. South Korea Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Southeast Asia Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. India Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Australia Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) List of Figures Figure 43. Latin America Late Stage Chronic Kidney Disease Drugs Market Size YoY (2017-2028) & (US$ Million) Figure 44. Latin America Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2017-2028) Figure 45. Latin America Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2017-2028) Figure 46. Latin America Late Stage Chronic Kidney Disease Drugs Market Size Share by Country (2017-2028) Figure 47. Mexico Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 48. Brazil Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 49. Middle East & Africa Late Stage Chronic Kidney Disease Drugs Market Size YoY (2017-2028) & (US$ Million) Figure 50. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Type (2017-2028) Figure 51. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Market Size Market Share by Application (2017-2028) Figure 52. Middle East and Africa Late Stage Chronic Kidney Disease Drugs Market Size Share by Country (2017-2028) Figure 53. Turkey Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 54. Saudi Arabia Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 55. UAE Late Stage Chronic Kidney Disease Drugs Market Size YoY Growth (2017-2028) & (US$ Million) Figure 56. AbbVie Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 57. Amgen Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 58. Ardelyx Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 59. AstraZeneca Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 60. Deltanoid Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 61. Akebia Therapeutics Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 62. Kyowa Hakko Kirin Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 63. OPKO Health Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 64. Vifor Pharma Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 65. Sanofi Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 66. Shield Therapeutics Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 67. Shire Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 68. Spectrum Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 69. ZS Pharma Revenue Growth Rate in Late Stage Chronic Kidney Disease Drugs Business (2017-2022) Figure 70. Bottom-up and Top-down Approaches for This Report Figure 71. Data Triangulation Figure 72. Key Executives Interviewed